Dabrafenib
(duh-BRA-feh-nib)
This page contains brief information about dabrafenib and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
| US Brand Name(s): |  | Tafinlar |
| | ||
| | ||
| FDA Approved: | | Yes |
Dabrafenib is approved to treat:
- Melanoma that cannot be removed by surgery or has metastasized (spread to other parts of the body). It is used only in patients who have a certain mutation in the BRAF gene.
Dabrafenib is also being studied in the treatment of other types of cancer.
More About DabrafenibDefinition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.
Research ResultsDrug Combination More Effective Than Single Drug for Advanced Melanoma - Information about the use of this drug to treat cancer.
Targeted Drug Shows Potential in Advanced Solid Tumors and Brain Metastases - Information about the use of this drug to treat cancer.
MEK: A Single Drug Target Shows Promise in Multiple Cancers - Information from NCI about this drug.
Clinical Trials Accepting PatientsFind Clinical Trials for Dabrafenib - Check for trials from NCI's list of cancer clinical trials now accepting patients.
Important: The drug information on this page is meant to be educational. It is not a substitute for medical advice. The information may not cover all possible uses, actions, interactions, or side effects of this drug, or precautions to be taken while using it. Please see your health care professional for more information about your specific medical condition and the use of this drug.
Back to Top